Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
|Articles|August 11, 2011
Advanced screening of 50/50 in California
Author(s)Lindsay Ray
Advertisement
One of our readers sent us an email letting us know about an advanced screening of 50/50, the upcoming Joseph Gordon-Levitt and Seth Rogen movie about a young man's cancer journey, in San Marcos, California. The screening will be held on Tuesday, Aug. 16 at 7 p.m. Go to
Advertisement
Related to this article
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease.
Ronald Chin reflects on hospitality, setting boundaries and accepting his body, and how his greatest strengths and struggles both come from one open heart.
Joy Maulik, MSN, FNP-C, discusses why he built the MyUrova app and how men with prostate, bladder, kidney or testicular cancer can prepare for visits, understand their risk and set expectations for life after treatment.
Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically significant.
Four phase 3 trials at ESMO 2026 brought news for people with small cell, EGFR, MET and KRAS G12C lung cancer, plus a caution about spacing out immunotherapy doses.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
Advertisement
Advertisement